Scheduled versus Pro Re Nata dosing in the VIEW trials

Gisbert Richard*, Jordi Monés, Sebastian Wolf, Jean François Korobelnik, Robyn Guymer, Michaella Goldstein, Christiane Norenberg, Rupert Sandbrink, Oliver Zeitz

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Fingerprint

Dive into the research topics of 'Scheduled versus Pro Re Nata dosing in the VIEW trials'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience